Since its discovery in late December 2019 in Wuhan (China), SARS-CoV-2 has been detected all over the world, including several variants. It is unique in terms of its high transmissibility, pathogenicity and mortality when compared to other coronaviruses.
BioGenes is participating in the global fight against COVID-19 by providing its knowledge and established technology in highly sophisticated antibody development for diagnostic purposes and research.
With Excellence in Antibody and ELISA Development, we would appreciate supporting your COVID-19 research, and development of assays and diagnostic tests. BioGenes’ personnel continue working in our labs with the goal of generating customized monoclonal and polyclonal antibodies suitable for the detection of SARS-CoV-2 proteins of choice, with high sensitivity and specificity. The development of anti-idiotypic antibodies (anti-ID), e.g. for use as assay controls, can be particularly challenging. BioGenes’ thorough understanding of anti-ID development and our great antibody track record makes us an optimal partner for COVID-19 related antibody projects. BioGenes also offers services for ELISA set up and qualification, e.g. for protein quantification to enhance production cell line development, complementing our antibody manufacturing know-how.
With recommended safety measures in place to prevent the spread of COVID-19, BioGenes is operating at normal speed. We can assure you of the highest level of quality and service for your upcoming projects. We would be happy to arrange a phone call with our experts from Project Management and the lab to discuss any details.